114 related articles for article (PubMed ID: 24554512)
1. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c-reactive protein, interleukin-6 and soluble vascular cell adhesion molecule-1 concentrations in women with polycystic ovary syndrome.
Dardzińska JA; Rachoń D; Kuligowska-Jakubowska M; Aleksandrowicz-Wrona E; Płoszyński A; Wyrzykowski B; Lysiak-Szydłowska W
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):118-25. PubMed ID: 24554512
[TBL] [Abstract][Full Text] [Related]
2. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
Rautio K; Tapanainen JS; Ruokonen A; Morin-Papunen LC
Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
5. Is the suppressive effect of cyproterone acetate on serum anti-Müllerian-hormone levels in women with polycystic ovary syndrome stronger than under oral contraceptive pill?
Plouvier P; Peigné M; Gronier H; Robin G; Catteau-Jonard S; Dewailly D
Gynecol Endocrinol; 2016 Aug; 32(8):612-616. PubMed ID: 26890873
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
7. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
[TBL] [Abstract][Full Text] [Related]
8. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
Kebapcilar L; Kebapcilar AG; Bilgir O; Taner CE; Bozkaya G; Yildiz Y; Sari I
Gynecol Endocrinol; 2011 Feb; 27(2):91-5. PubMed ID: 20528207
[TBL] [Abstract][Full Text] [Related]
9. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Wang QY; Song Y; Huang W; Xiao L; Wang QS; Feng GM
Chin Med J (Engl); 2016 Apr; 129(8):883-90. PubMed ID: 27064030
[TBL] [Abstract][Full Text] [Related]
11. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
[TBL] [Abstract][Full Text] [Related]
12. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Ibáñez L; De Zegher F
Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
[TBL] [Abstract][Full Text] [Related]
13. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Luque-Ramírez M; Escobar-Morreale HF
Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
[TBL] [Abstract][Full Text] [Related]
14. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
15. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
16. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
17. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
18. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
19. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers.
Christakou C; Kollias A; Piperi C; Katsikis I; Panidis D; Diamanti-Kandarakis E
Hormones (Athens); 2014; 13(4):488-97. PubMed ID: 25555182
[TBL] [Abstract][Full Text] [Related]
20. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).
Bilgir O; Kebapcilar L; Taner C; Bilgir F; Kebapcilar A; Bozkaya G; Yildiz Y; Yuksel A; Sari I
Intern Med; 2009; 48(14):1193-9. PubMed ID: 19602786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
